The CGPA-Member Teriflunomide Enhanced Pharmacovigilance Pregnancy Active Surveillance Program.
Physicians are encouraged to enroll pregnant women in the Enhanced Pharmacovigilance Pregnancy Active Surveillance Program.
TERIFLUNOMIDE is indicated as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS). It should only be prescribed by clinicians who are experienced in the diagnosis and management of multiple sclerosis. TERIFLUNOMIDE may increase the risk of fetal death or teratogenic effects when administered to pregnant women which includes pregnant individuals who are or were taking teriflunomide or who were suspected to have teriflunomide exposure via the semen of a male partner taking teriflunomide.
Please download the required form as per the Adverse Reaction and send it to
Email: Safety.canada@marcanpharma.com or info@marcanpharma.com
e-FAX: 1-613-777-1025
If you have any questions please reach out to us via our toll free number 1-855-627-2261
